Sofosbuvir/Velpatasvir and Pravastatin Interaction

Understanding the Sofosbuvir/Velpatasvir and Pravastatin Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Sofosbuvir/Velpatasvir belongs to the NS5B/NS5A Inhibitor (HCV) class and Pravastatin belongs to the HMG-CoA Reductase Inhibitor (Statin) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: This medication increases the amount of pravastatin that stays in your blood, which makes muscle injury more likely. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Sofosbuvir/Velpatasvir has 33 total documented interactions on file in this dataset, and Pravastatin has 16. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: If you take these medicines together, do not take more than 40 mg of pravastatin each day. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Sofosbuvir/Velpatasvir or Pravastatin based on a web page, speak with your prescriber or pharmacist before making any change.